My limited mobility makes it hard to visit loved ones during the holidays

Study examines intermittent use of corticosteroids in DMD boys

Corticosteroids may cause fewer unwanted brain changes in boys with Duchenne muscular dystrophy (DMD) if they are given on and off at 10-day intervals, rather than at daily doses, an imaging study found. “Brain volumetrics [volume measurements] are more profoundly affected in patients treated with a daily corticosteroid…

EDG-5506 wins FDA orphan drug designation for DMD and BMD

The U.S. Food and Drug Administration (FDA) has granted both orphan drug and rare pediatric disease designations to Edgewise Therapeutics‘ EDG-5506 as a potential treatment for Duchenne muscular dystrophy (DMD). EDG-5506 also was awarded FDA orphan drug status for Becker muscular dystrophy (BMD) as a possible…

The timing, choices, and challenges of managing clinical trials

Note: This column describes the author’s sons’ experiences with a trial dose of Translarna (ataluren) in the U.S. Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. I’m a mother to three sons with Duchenne muscular dystrophy (DMD): Max, 18,…